Ju Bo Liu

SciGen Pte Ltd. engages in the development, manufacturing, and marketing of biopharmaceutical products. It operates through following segments: Singapore, Australia, Korea, Thailand, Philippines, China, and Others. The Singapore segment comprises of corporate office functions, sales, and marketing. The Australia, Korea, Thailand, and Philippines segments deal with sales and marketing activities. The China segment is involved in regulatory activities. The Others segment covers operations on in Indonesia, Pakistan, Vietnam, Hong Kong, Myanmar, Malaysia, and profit sharing income on sale of insulin. The firm's products include SciLin, SciTropin A, SciLocyte, SciTrace 5 Injection, and Heri Injection. The company was founded by Saul Akerib Mashaal in 1988 and is headquartered in Singapore.

Part of Yifan Pharmaceutical Co., Ltd., NovoTek Pharmaceuticals Ltd. is a Chinese pharmaceutical company that manufactures pharmaceutical products. The private company is based in Hong Kong, Hong Kong. The company was founded by Ju Bo Liu. Ju Bo Liu has been the CEO since incorporation. NovoTek Pharmaceuticals was acquired by Yifan International Pharmaceutical Co., Ltd. from Merrylake International Ltd. on January 25, 2018 for $20.60 million.

ITabMed Co., Ltd. is a Chinese clinical-stage biotech company that focuses on the discovery and development of immunotherapy products to treat cancer. The company is based in Shanghai, China. ITabMed Co. was founded in 2020 by Xiaoqiang Yan, who has been the CEO since 2020.